Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

A Collision Tumor Involving a Primary Leiomyosarcoma of the Lower Extremity and a Metastatic Medullary Thyroid Carcinoma: A Case Report.

Austin DC, Wu JS, Spentzos D, Goldsmith JD, Anderson ME.

JBJS Case Connect. 2017 Oct-Dec;7(4):e90. doi: 10.2106/JBJS.CC.17.00041.

PMID:
29286973
2.

Expression and Therapeutic Potential of SOX9 in Chordoma.

Chen H, Garbutt CC, Spentzos D, Choy E, Hornicek FJ, Duan Z.

Clin Cancer Res. 2017 Sep 1;23(17):5176-5186. doi: 10.1158/1078-0432.CCR-17-0177. Epub 2017 Jun 12.

PMID:
28606919
3.

An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets.

Hill KE, Kelly AD, Kuijjer ML, Barry W, Rattani A, Garbutt CC, Kissick H, Janeway K, Perez-Atayde A, Goldsmith J, Gebhardt MC, Arredouani MS, Cote G, Hornicek F, Choy E, Duan Z, Quackenbush J, Haibe-Kains B, Spentzos D.

J Hematol Oncol. 2017 May 15;10(1):107. doi: 10.1186/s13045-017-0465-4.

4.

A network model for angiogenesis in ovarian cancer.

Glass K, Quackenbush J, Spentzos D, Haibe-Kains B, Yuan GC.

BMC Bioinformatics. 2015 Apr 11;16:115. doi: 10.1186/s12859-015-0551-y.

5.

MicroRNA-155 expression is independently predictive of outcome in chordoma.

Osaka E, Kelly AD, Spentzos D, Choy E, Yang X, Shen JK, Yang P, Mankin HJ, Hornicek FJ, Duan Z.

Oncotarget. 2015 Apr 20;6(11):9125-39.

6.

Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma.

Duan Z, Shen J, Yang X, Yang P, Osaka E, Choy E, Cote G, Harmon D, Zhang Y, Nielsen GP, Spentzos D, Mankin H, Hornicek F.

J Orthop Res. 2014 May;32(5):695-701. doi: 10.1002/jor.22589. Epub 2014 Feb 5.

7.

Next-generation sequencing and microarray-based interrogation of microRNAs from formalin-fixed, paraffin-embedded tissue: preliminary assessment of cross-platform concordance.

Kelly AD, Hill KE, Correll M, Hu L, Wang YE, Rubio R, Duan S, Quackenbush J, Spentzos D.

Genomics. 2013 Jul;102(1):8-14. doi: 10.1016/j.ygeno.2013.03.008. Epub 2013 Apr 3.

8.

Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis.

Schwede M, Spentzos D, Bentink S, Hofmann O, Haibe-Kains B, Harrington D, Quackenbush J, Culhane AC.

PLoS One. 2013;8(3):e57799. doi: 10.1371/journal.pone.0057799. Epub 2013 Mar 11.

9.

MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32.

Kelly AD, Haibe-Kains B, Janeway KA, Hill KE, Howe E, Goldsmith J, Kurek K, Perez-Atayde AR, Francoeur N, Fan JB, April C, Schneider H, Gebhardt MC, Culhane A, Quackenbush J, Spentzos D.

Genome Med. 2013 Jan 22;5(1):2. doi: 10.1186/gm406. eCollection 2013.

10.

A microRNA activity map of human mesenchymal tumors: connections to oncogenic pathways; an integrative transcriptomic study.

Fountzilas E, Kelly AD, Perez-Atayde AR, Goldsmith J, Konstantinopoulos PA, Francoeur N, Correll M, Rubio R, Hu L, Gebhardt MC, Quackenbush J, Spentzos D.

BMC Genomics. 2012 Jul 23;13:332. doi: 10.1186/1471-2164-13-332.

11.

Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer.

Fountzilas E, Markou K, Vlachtsis K, Nikolaou A, Arapantoni-Dadioti P, Ntoula E, Tassopoulos G, Bobos M, Konstantinopoulos P, Fountzilas G, Spentzos D.

Ann Oncol. 2012 Aug;23(8):2146-53. doi: 10.1093/annonc/mdr576. Epub 2012 Jan 4.

12.

Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma.

Kelly AD, Breitkopf SB, Yuan M, Goldsmith J, Spentzos D, Asara JM.

PLoS One. 2011;6(10):e25357. doi: 10.1371/journal.pone.0025357. Epub 2011 Oct 3.

13.

Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL, Cannistra SA.

Cancer Res. 2011 Aug 1;71(15):5081-9. doi: 10.1158/0008-5472.CAN-10-4668. Epub 2011 Jun 15.

14.

Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer.

Konstantinopoulos PA, Cannistra SA, Fountzilas H, Culhane A, Pillay K, Rueda B, Cramer D, Seiden M, Birrer M, Coukos G, Zhang L, Quackenbush J, Spentzos D.

PLoS One. 2011 Mar 29;6(3):e18202. doi: 10.1371/journal.pone.0018202.

15.

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA.

J Clin Oncol. 2010 Aug 1;28(22):3555-61. doi: 10.1200/JCO.2009.27.5719. Epub 2010 Jun 14. Erratum in: J Clin Oncol. 2010 Nov 10;28(32):4868.

16.

Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance.

Konstantinopoulos PA, Fountzilas E, Goldsmith JD, Bhasin M, Pillay K, Francoeur N, Libermann TA, Gebhardt MC, Spentzos D.

PLoS One. 2010 Apr 1;5(4):e9747. doi: 10.1371/journal.pone.0009747.

17.

Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28.

Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D, Avigan D.

J Immunother. 2010 Feb-Mar;33(2):155-66. doi: 10.1097/CJI.0b013e3181bed253.

18.

Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers.

Burga LN, Tung NM, Troyan SL, Bostina M, Konstantinopoulos PA, Fountzilas H, Spentzos D, Miron A, Yassin YA, Lee BT, Wulf GM.

Cancer Res. 2009 Feb 15;69(4):1273-8. doi: 10.1158/0008-5472.CAN-08-2954. Epub 2009 Feb 3.

19.

Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndrome.

Prall WC, Czibere A, Grall F, Spentzos D, Steidl U, Giagounidis AAN, Kuendgen A, Otu H, Rong A, Libermann TA, Germing U, Gattermann N, Haas R, Aivado M.

Int J Hematol. 2009 Mar;89(2):173-187. doi: 10.1007/s12185-008-0242-9. Epub 2009 Jan 20.

PMID:
19152102
20.

Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer.

Konstantinopoulos PA, Fountzilas E, Pillay K, Zerbini LF, Libermann TA, Cannistra SA, Spentzos D.

BMC Med Genomics. 2008 Nov 28;1:59. doi: 10.1186/1755-8794-1-59.

21.

Gene-expression profiling in epithelial ovarian cancer.

Konstantinopoulos PA, Spentzos D, Cannistra SA.

Nat Clin Pract Oncol. 2008 Oct;5(10):577-87. doi: 10.1038/ncponc1178. Epub 2008 Jul 22. Review.

PMID:
18648354
22.

Reproducibility of proteomic profiles over 3 years in postmenopausal women not taking postmenopausal hormones.

Tworoger SS, Spentzos D, Grall FT, Liebermann TA, Hankinson SE.

Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1480-5. doi: 10.1158/1055-9965.EPI-07-2725.

23.

Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.

Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, Wells M, Guerrero M, Asara JM, Libermann TA, Afdhal NH.

Clin Cancer Res. 2008 Jan 15;14(2):470-7. doi: 10.1158/1078-0432.CCR-07-0586.

24.

Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer.

Jones J, Otu HH, Grall F, Spentzos D, Can H, Aivado M, Belldegrun AS, Pantuck AJ, Libermann TA.

J Urol. 2008 Feb;179(2):730-6. Epub 2007 Dec 20.

25.

IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.

Spentzos D, Cannistra SA, Grall F, Levine DA, Pillay K, Libermann TA, Mantzoros CS.

Endocr Relat Cancer. 2007 Sep;14(3):781-90.

26.

Age-related transcription levels of KU70, MGST1 and BIK in CD34+ hematopoietic stem and progenitor cells.

Prall WC, Czibere A, J├Ąger M, Spentzos D, Libermann TA, Gattermann N, Haas R, Aivado M.

Mech Ageing Dev. 2007 Sep;128(9):503-10. Epub 2007 Jul 4.

PMID:
17714764
27.

Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy.

Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, Knowler WC, Monroy M, Libermann TA, Karumanchi SA, Thadhani R.

Diabetes Care. 2007 Mar;30(3):638-43.

PMID:
17327333
28.

Analysis and robot pipelined automation for SELDI-TOF mass spectrometry.

Alterovitz G, Aivado M, Spentzos D, Libermann TA, Ramoni M, Kohane IS.

Conf Proc IEEE Eng Med Biol Soc. 2004;4:3068-71.

PMID:
17270926
29.

Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.

Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F, Giagounidis AA, Klement G, Steidl U, Otu HH, Czibere A, Prall WC, Iking-Konert C, Shayne M, Ramoni MF, Gattermann N, Haas R, Mitsiades CS, Fung ET, Libermann TA.

Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1307-12. Epub 2007 Jan 12.

30.

Formative evaluation of a prototype system for automated analysis of mass spectrometry data.

Fananapazir N, Li M, Spentzos D, Aliferis CF.

AMIA Annu Symp Proc. 2005:241-5.

31.

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA.

J Clin Oncol. 2005 Nov 1;23(31):7911-8. Epub 2005 Oct 3.

PMID:
16204010
32.

Gene signatures of progression and metastasis in renal cell cancer.

Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA.

Clin Cancer Res. 2005 Aug 15;11(16):5730-9.

33.

Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling.

Aivado M, Spentzos D, Alterovitz G, Otu HH, Grall F, Giagounidis AA, Wells M, Cho JY, Germing U, Czibere A, Prall WC, Porter C, Ramoni MF, Libermann TA.

Clin Chem Lab Med. 2005;43(2):133-40.

PMID:
15843205
34.

Gene expression signature with independent prognostic significance in epithelial ovarian cancer.

Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA.

J Clin Oncol. 2004 Dec 1;22(23):4700-10. Epub 2004 Oct 25. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15505275
35.

Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients.

Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJ.

Clin Cancer Res. 2003 Aug 15;9(9):3282-7.

36.

Adult height and menarcheal age of young women in Greece.

Georgiadis E, Mantzoros CS, Evagelopoulou C, Spentzos D.

Ann Hum Biol. 1997 Jan-Feb;24(1):55-9.

PMID:
9022906

Supplemental Content

Loading ...
Support Center